Exelixis-Phase 2 Study of Zanzalintinib in Recurrent or Progressive Meningioma (XL092-201)

Who Can Participate in the Study?

Age Group
Adults

Study Details

Full Title
A Phase 2, Single-Arm, Multicenter, Open-Label Study of Zanzalintinib in Participants With Recurrent or Progressive Meningioma (XL092-201)
Principal Investigator
Headshot of Katherine Barnett Peters
Professor of Neurosurgery
Protocol Number
IRB: PRO00119908
NCT: NCT07428616
Phase
Phase II
ClinicalTrials.gov
Enrollment Status
OPEN TO ACCRUAL
Participate